Clinical trials
Bronchial Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
55 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 7 |
| 2017 | 7 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Recruiting | 10 |
| Terminated | 10 |
| Unknown status | 9 |
| Active, not recruiting | 7 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 6 |
| Revolution Medicines, Inc. | 6 |
| Blueprint Medicines Corporation | 3 |
| Eli Lilly and Company | 3 |
| Syndax Pharmaceuticals | 3 |
| Hoffmann-La Roche | 2 |
| Iovance Biotherapeutics, Inc. | 2 |
| Jiangsu HengRui Medicine Co., Ltd. | 2 |
| Qingdao Central Hospital | 2 |
| St. Olavs Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bronchial Neoplasms | 55 |
| Carcinoma, Non-Small-Cell Lung | 44 |
| Lung Neoplasms | 42 |
| Lung Diseases | 35 |
| Neoplasms | 34 |
| Respiratory Tract Neoplasms | 34 |
| Thoracic Neoplasms | 33 |
| Carcinoma, Bronchogenic | 30 |
| Respiratory Tract Diseases | 30 |
| Neoplasms by Site | 29 |
Trials
Showing 26 to 50 of 55. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.